Analysis and utility of pretreatment and posttreatment total body iodine-131 scans in patients with thyroid carcinoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17031-e17031
Author(s):  
S. Billan ◽  
H. Nasrallah ◽  
R. Abdah-Bortnyak ◽  
A. Kuten
Keyword(s):  
Thyroid Carcinoma ◽  
Lymph Node Involvement ◽  
Differentiated Thyroid Carcinoma ◽  
Low Risk ◽  
Extracapsular Extension ◽  
Additional Information ◽  
Risk Patients ◽  
Node Involvement ◽  
Well Differentiated ◽  
Total Body

e17031 Background: The purpose of this study was to evaluate the efficacy of post-I-131 treatment total body scans. Methods: The records of 108 consecutive patients with thyroid carcinoma treated by surgery and postoperative I-131 were reviewed. All patients underwent a postoperative diagnostic total body I-131 and post I-131 therapy scintigraphies .83% of patients were considered low risk according to AMES (age, metastasis, extracapsular extension, size) criteria. Results: The postoperative diagnostic total body I-131 scintigraphy revealed uptake in the neck in 95 out of 108 patients (88%). Three patients had lung and mediastinal uptake in known sites of metastatic disease. Additional foci of neck, mediastinal and lung uptake were revealed in the post-131 therapy total body scintigraphies in ten patients ( 9.3%). Variables found to correlate significantly with additional uptake on the post-I131 therapy total body scintigraphies were tumor size >4cm, lymph-node involvement and extracapsular extension. Conclusions: Post- I-131 therapy scans yielded additional information in 9.3% of the patients treated by postoperative I-131 for well differentiated thyroid carcinoma. The value of posttreatment scintigraphies is questionable in low risk patients. No significant financial relationships to disclose.

scholarly journals Isthmusectomy for well-differentiated thyroid carcinoma located to the isthmus: A report of two cases and review of the literature

Medwave ◽  
2021 ◽  
Vol 21 (10) ◽  
pp. e8493-e8493
Author(s):  
Roberto Ignacio Olmos Borzone ◽  
Jorge Andrés López Ruiz-Esquide ◽  
Francisco Domínguez Covarrubias ◽  
José Miguel Domínguez Ruiz-Tagle
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Therapeutic Option ◽  
Lymph Node Involvement ◽  
Differentiated Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Node Involvement ◽  
Well Differentiated ◽  
Prophylactic Lymph Node Dissection

Papillary thyroid cancer is the most common endocrine malignancy, and due to its favorable prognosis, the extent of surgery has been a matter of debate. About 10% of these tumors are located in the thyroid isthmus, with no specific management in current guidelines. In the last decades, isthmusectomy has been proposed as a therapeutic option for isthmic papillary thyroid carcinoma, although there is no consensus on its management. We present two cases of patients from our institution with solitary isthmic papillary thyroid carcinoma without clinical macroscopic extrathyroidal extension or clinical-radiological lymph node involvement who were treated with isthmusectomy without prophylactic lymph node dissection. Neither of them had any postoperative complications. Both had an intermediate risk of recurrence due to aggressive variants. None of them had signs of recurrence during follow-up. We intend to show that isthmusectomy seems to be an effective and safe surgical alternative in selected patients through these cases.

Impact of Risk Organ Involvement on Outcome in Langerhans Cell Histiocytosis (LCH)

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4652-4652 ◽  
Author(s):  
Satyendra Katewa ◽  
Anupam Sachdeva ◽  
Veronique Dinand ◽  
Satya Prakash Yadav
Keyword(s):  
Bone Marrow ◽  
Lymph Node Involvement ◽  
Low Risk ◽  
Lung Involvement ◽  
Isolated Lung ◽  
Risk Patients ◽  
Node Involvement ◽  
Group A ◽  
Bony Involvement ◽  
Group B

Abstract Objectives: To compare the outcome in children with low risk vs. risk LCH and to evaluate the impact of individual risk organ on outcome. Material and Methods: Medical records of 52 patients were reviewed retrospectively (1992 to 2007). Patients were classified into 2 groups: A-low risk (bone, skin and lymph node involvement), B-risk patients (lungs, liver, spleen and bone marrow involvement). Group B further subdivided in B1-isolated lung involvement, B2-liver, bone marrow or both without lung, B3-lung involvement with liver and/or bone marrow. Patients were treated as per histiocytosis society protocols. Results: There were 31 Males and 21 Females. Mean age at presentation was 4.8 yrs (range 1 month to 15.5 yrs). There were 21 patients in Group A and 31 in Group B with 0 (0%) and 6 (19%) deaths respectively. Overall mortality was 6/52 (11.5%). In group A, 6 patients had skin and lymph node involvement, 6 had unifocal bony involvement and 9 multifocal. Out of these 15 (bony involvement) patients 4 had otitis media and 5 diabetes insipidus. There were 9 patients in Group B1, 18 in Group B2 and 4 in Group B3 with mortality of 0 (0%), 4 (22.2%) and 2 (50%) respectively. Comparison of mortality in risk patients vs. low risk patients approached statistical significance (19.4% vs. 0%, p=0.069). Mortality difference within the 3-subgroups of risk patients was not statistically significant (p=0.097). Conclusion: Outcome is worse if risk organs are involved. However, isolated lung involvement had trend towards better outcome.

Serum thyroglobulin levels predict total body iodine scan findings in patients with treated well-differentiated thyroid carcinoma

1980 ◽  
Vol 69 (3) ◽  
pp. 401-407 ◽  
Author(s):  
M.Arthur Charles ◽  
Leonard E. Dodson ◽  
Nancy Waldeck ◽  
Fred Hofeldt ◽  
Nasser Ghaed ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Well Differentiated ◽  
Total Body ◽  
Iodine Scan

scholarly journals Utility of Stimulated Thyroglobulin in the Differentiate Thyroid Cancer

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A874-A874
Author(s):  
Fabiola Romero ◽  
Sandra Galeano ◽  
Francisco Cabrera ◽  
Liliana Vigo ◽  
Carlos Laterza ◽  
...  
Keyword(s):  
High Risk ◽  
Radioactive Iodine ◽  
Differentiated Thyroid Carcinoma ◽  
Low Risk ◽  
Intermediate Risk ◽  
Body Scan ◽  
Risk Patients ◽  
Group A ◽  
Total Body ◽  
Group B

Abstract Introduction: The treatment of differentiated thyroid cancer has changed considerably, total thyroidectomy and radioactive iodine ablation represented the initial treatment for these patients, currently with a great debate around the choice of which patient should undergo ablation with radioactive iodine in the post-surgical period. Objective: To determine the values of stimulated thyroglobulin (in hypothyroidism) in patients with differentiated thyroid carcinoma who have had surgery and its relationship with the ATA 2015 recurrence risk stratification and the presence of distant or locoregional metastasis in post ablative total body scan with I131 Methodology: Retrospective study, which included patients with differentiated thyroid carcinoma, patients who have had total thyroidectomy surgery and subsequent ablation with I131 in 45 days at the Central Hospital of Instituto de Prevision Social, from 2011 to 2018. There were evaluated: post-surgical thyroglobulin dosage in hypothyroidism, antithyroglobulin antibody measurement, and total body scan results at 72 hours post ablation with I131. There were excluded: Patients with positive antithyroglobulin antibodies, eu /hyperthyroidism, or incomplete data. Results: 100 patients conformed by women (88.0%), whose average age was 44.7 (± 16.1), intermediate risk 60%, high risk 31% and low risk 9%. According to the stimulated thyroglobulin values, 3 groups were classified: Group A thyroglobulin less than 1 ng/dl 32%, Group B 1 to 10 ng/dl 39%, Group C greater than 10 ng/dl 29%. Of the patients at intermediate risk n: 60, 23 (38%) belonged to group A, 27 (45%) to group B and 10 (17%) to group C. Of high-risk patients n: 31, 7 (22%) belonged to group A, 8 (26%) to group B, and 16 (52%) to group C. Of low risk patients n: 9, 2 (22%) belonged to group A, 4 (44%), group B, and 3 (33%) to group C. Post-ablative body scan detected locoregional or distant metastases in 23 (23%) patients, of which 2 (8.6%) belonged to group A, 6 (26%) to group B, 15 (65%) to group C. They were intermediate risk 10 (43%) and high risk 13 (57%) of them. No low-risk patient presented a positive RCT. There was found a relationship between thyroglobulin and high ATA risk (p <0.05) with positive RCT. Association between thyroglobulin> 10ng / dL and the presence of metastasis (p = 0.0001), Exp (B) 15.1 with R2 25 and 35%. Conclusion: A stimulated postoperative thyroglobulin dosage greater than 10 ng/ dL increases the chances of recurrence 15 times, with 25 to 37% chance of it. So, it would be important to consider ablation with iodine 131 in this type of patients.

Sign in / Sign up

Export Citation Format

Share Document